INTRODUCTION
The abnormalities in calcium and phosphate balance affecting children with chronic renal insufficiency have been recognized for over a century (1) . Intestinal malabsorption of calcium is a characteristics of uremic children and results in severe secondary hyperparathyroidism. This finding indicates dysfunction of the vitamin D endocrine system (2) . The additional finding that these children are resistant to conventional doses of vitamin D can best be explained by the discovery of Kodicek and lawson, Norman and Haussler, and Deluca's group that the kidney is essential in the biotransformation of vitamin D to more active metabolites (3) .
This endocrine function of the kidney now removes vitamin D as "a vitamin", because one of the renal synthesized metabolites -1,25(OH)2 vitamin D (1,25(OH)2D)-acts at target tissues remote from the site of its production, as for example in the intestine and bone. Hormonally active vitamin D appears to be 1,25(OH)2D since it leads to active intestinal calcium and phosphate absorption, since it releases calcium from the greatest body depot of mineralsbone -and since it probably contributes to calcium and phosphate conservation by the kidney (4) . Again, because many other vitamin D metabolitesamong them 24,25(OH)2 vitamin D; 25,1 ,25(OH)2 vitamin D and 25(OH)D -23,26 -lactone -as well as 1,25(OH)2D, are produced by the kidney, it is to be anticipated that the blood levels of these metabolites would be reduced in uremia. Indeed, at least 3 groups have reported reduced circulating values of 1,25(OH)2D in children with renal diseases whose The International Journal Of Artificial Organs / Vol. 9 no. 6, 1986/ p.p. 369-376 creatinine clearance is under 50 ml/min/1.73M 2 (5-7), and a significant decline in 24,25(OH)2D has also been reported as well (5) . In end-stage renal disease, the values of 1,25(OH)2D and 24,25(OH)2D fall even farther and many of the fatures of vitamin D deficiency develop (8) . This review is an attempt to outline how changes in the circulating level of 1,25(OH)2D resulting from uremia cause malfunction of the vitamin D -endocrine system and how this in turn influences mineral balance in the child with end-stage renal failure.
THE VITAMIN D -ENDOCRINE SYSTEM
Under usual circumstances, hypolcalcemia leads to secretion of parathyroid hormone (PTH), which will stimulate the kidney to produce more 1,25(OH)2D. This metabolite increases local bone resorption, net active calcium and phosphate absorption by the intestine, and renal tubular reasorbtion of calcium and possibly of phosphate (2, 3). These actions raise the level of calcium in the extracellular fluid; because the increased PTH promotes phophaturia so that phosphate levels become normal also. The higher serum calcium reduces PTH secretion, renal 1a-hydroxylase activity, and 1,25(OH)2D synthesis, thus completing the feedback loop.
A second limb of this system is rsonsive to hypophosphatemia, which of itself stimulates 1ahydroxylase activity despite the absence of PTH secretion and PTH per se. As PTH levels are normal, bone resorption does not occur and urinary phosphate excretion remains low. However, the increased circulating levels of 1,25(OH)2D activates intestinal phosphate resorption (as well as calcium) thereby restoring serum phosphate to normal. In the absence of PTH, the additional calcium is excreted in the urine and the restoration of serum phosphate level dampens 1a-hydroxylase activity in another feedback loop ..
On balance both feedback loops result in normalization of serum (extracelular) calcium and phosphate levels. As well, when serum calcium and phosphate are normal, the production of the renal vitamin D metabolite, 24,25(OH)2D, is stimulated.
If this slowly turned over metabolite is important in bone mineralization as has been suggested in previous studies (8) then bone mineral deposition is also favored.
MINERAL IMBALANCE IN UREMIA
In the child with end-stage renal failure, considerable evidence exists that there is impairment in intestinal calcium absorption, both by the finding of hypocalcemia and by direct measurement of intestinal calcium absorption performed over 50 years ago (8) . The child with a creatinine clearance of under 20 ml/min/1.73M2 will ordinarily have hypocalcemia and hyperphosphatemia for the following reasons: first, the intestine is the major site for the rgulation of body calcium stores and 1,25(OH)2D appears to be the hormone regulating this process, unless the patient ingests more than 2.5 to 3.0 gm of elemental calcium daily so that passive intestinal calcium uptake can assure positive calcium balance. With the reduction in 1,25(OH)2 synthesis prevalent in uremia, calcium in usual cannot prevent negative calcium balance from developing. Phosphate, by way of contrast, is not regulated by the intestine, but rather in the kidney. Gut absorption of this minerai is unchanged and, as the GFR falls, the serum values rise progressively despite the high levels of imunoreactive PTH. Thus on balance, hypocalcemia and hyperphosphatemia develop along with a very high level of PTH, low levels of 1,25(OH)2D and radiologic evidence of osteopenia.
The nature of the bone defect in end-stage disease is very complex. It involves increased bone resorption -as evidenced by osteitis fibrosa cysticaand decreased bone formation rates -as evidenced by widened osteoid seams and osteomalacia (9) . Other factors contributions to the bone abnormalities found in childhood uremia include aluminum deposition, oxalate deposition, and impaired somatomedin activity (8) (9) (10) . Bone histologic studies in children with uremia are few (1), but the same lesions as found in adults appear to predominate. Nevertheless, bone mineral status in children with renal disease is abnormally low (12) and the bone itself fails to be a reasonable enough reservoir of mineral to prevent hypocalcemia. The myopathy of uremia has reserve origin and may involve the myopathy 370 characteristic of vitamin D-deficiency, bone pain, bone aluminum deposition, and the poor nutritional status of uremic children.
PATHOGENESIS OF UREMIC OSTEODYS-TROPHY
At least 2 factors contribute to mineral imbalance and the development of osteodystrophy in uremic subjects -the retention of phosphate and abnormalities in vitamin D metabolism. At present it is not certain which of these factors is of principal importance, but both factors impinge on one another with the result that the vitamin D endocrine scheme outlined above is disrupted.
Hyperphosphstemia, arising because the intestine is readily permeable to phosphate, plays a pivotal role in the development and maintenance of secondary hyperparathyroidism related to the fall in the plasma ionized calcium level. Slatopolsky and coworkers (14) have recently shown in studies of cultured parathyroid glands from uremic animals that hypocalcemia, per se, may not even be required. Xxperimental studies in uremic dogs have indicated that the restriction of dietary phosphate intake in proportion to the reduction in GFR prevents the development of secondary hyperparathyroidism (15) . Further, in adult patients preliminary results indicate tha reduction of phosphate intake early in the course of renal failure will be associated with a fall in PTH levels and some amelioration with the development of bone disease (16, 17 dose of aluminum hydroxide (60 mg/kg/24h) ( Fig. 1 ). However, in three children with moderate renal insufficiency (clearance between 22 and 38 ml/min/ 1.73M2) the same manipulationn led to a significantly higher level of 1,25(OH)2D. In Portale's study, the dietary restriction of phosphate in a much larger group of children with moderate renal insufficiency not only resulted in higher 1,25(OH)2D values but induced a change in the serum concentration of iPTH (18) . In other words, phosphate supplementation resulted in higher iPTH levels and restriction in lower iPTH values. As well, supplementation of phosphate resulted in a fall in 1,25(OH)2D values. Taken together, these data are consistent with the notion that the hypocalcemia of renal insufficiency may be caused by the inflence of phosphate on the synthesis of 1,25(OH)2D. These data further imply that the synthesis of 1,25(OH)2D and other renal metabolites is influenced by the degree of renal imparment. This is the case and the serum level of1,25(OH)2D is lowest in child- ren with severe impairment of renal function (Fig.  2) , despite the fact that the immunoreactive PTH levels are very high ( Fig. 3 ) and that these patients are usually quite hypocalcemlic. Thus, despite these signals which ordinarily stimulate the synthesis of 1,25(OH)2D, the vitamin D endocrine system is dysfunctional and the level of this hormone do not rise. The values of 24,25(OH)2D are also reduced in uremic subjects (5) . As a consequence, if this metabolite participates in bone meneralization as suggested by some investigators, then uremia is associated with a deficiency of this metabolite. With our present knowledge it is difficult to appreciate the interplay between these two vitamin D metabolites produced in the kidney, but most clinical trials to date have not indicated that the combination of 1,25(OH)2D and 24,25(OH)2D is a more efficacious form of' therapy than 1,25(OH)2D or high dose vitamin d 2 alone (21) .
It has recently been reported that the extrarenal sites of 1,25(OHlzD synthesis may account for low, but measurable, levels of 1,25(OH)20 in anephric individuals. Using both a receptor assay after high pressure liquid chromatography and separate bioassay, Lambert et al (22) reported serum 1,25(OH)20 values ranging from 3.2 to 23.8 pg/ml. we carefully examined the serum values for 25(OH)02 and 03 and 1,25(OH)20 in 5 anephric hemodialyzed children (20) . As indicated in Figure 4 , the serum values for 1,25(OH)20 were nondetectable in each of the 5 patients, but 2 patients had a single serum sample with a value of 12 pg/ml. Based on these results and our previous data (5), we do not feel that circu-lating values of 1,25(OH)20 is present in anephric children.
Another factor that may play an important role in the pathogenesis of osteodystrophy, particularly in patients with longstanding uremia or who have experienced prolonged diaytic therapy, is the potential toxicity of aluminum (23) . First recognized as an important factor in dialysis encephalopathy (24, 25) , it is now apparent that the bones of patients receiving hemodialysis in centers using high aluminum content water or infants and young children who are administered high levels of oral aluminum hydroxide Chesney will contain extensive levels of aluminum (23, (26) (27) (28) . These latter studies in children who have never undergone dialysis have led to the assumption, as yet unproven, that the gut of young children is perhaps more permeable to aluminum and that these children may be at greter risk for aluminum-induced osteomalacia. It is clear, however, that the portion of dietary aluminum absorbed by the gut is ordinarily excreted by the kidney; thus, aluminum is retained by patients withrenal insufficiency.
The bone lesion associated with high bone aluminum content is osteomalacia, or bone undermineralization (29) . When bone turnover studies are carried out subjects with high bone aluminum levels, they almost consistently demonstrate low bone turnover rates (23, 29) . Despite the appreciation that aluminum is associated with this type of osteomalacia, the pathogenesis of this disorder is not appreciated. Regardless of pathogenesis, at least 4 approaches can be taken to prevent aluminum-asociated osteomalacia. Reverse osmosis of dialysate is an important first step. Aluminum-containing phosphate binding agents should be used with caution. There is a current trend to try to block phosphate absorption by using high doses of calcium carbonate. However, no controlled trial of this agent in children has been published. unfortunately, the amount of calcium carbonate needed to block intestinal phosphate absorption is so high that hypercalcemia is frequent, particularly if vitamin D analogs are also being administered. Finally, aluminum can be removed from bone by the use of the chelating agent desferrioxamine (DFO) (30) . Preliminary studies in children indicate that DFO at a dose of 40 mg/kg/24 hours may actually remove aluminum from bound tissue sites; this aluminum can then exit into the dialysate (31).
THERAPY OF MINERAL HOMEOSTATIC DEFECTS
The abnormalities of mineral homeostasis that accompany uremia can, at least in part, be improved by replacement of the vitamin D analog whose synthesis is impaired and by the avoidance of high doses of aluminum. The first principle of therapy is to improve intestinal calcium absorption. This is ac-complished by increasing dietary calcium intake, by reducing phosphare intake and by the use of vitamin D analogs. Several of these analogs -1,25(OH)2D, 1a(OH)D and dhydrotachysterol (DHT) -replace the 1a-hydroxygroup that is lost with the progressive reduction in renal mass. The therapeutic administration of these compounds has generally improved our capacity to treat renal osteodystrophy, since massive amounts of vitamin D 2 or D 3 are required to reverse calcium malabsorption in uremia. Indeed, as such as 50,000 to 100,000 IU of vitamin D may be required to reverse the defects in mineral homeostasis in uremic subjects (32) . The provision of only a fraction of a microgram of 1,25(OH)2D to a uremic child will increase serum calcium concentration by increasing intestinal calcium absorption and by reducing fecal calcium losses (32) . In addition, the therapy of childhood uremic osteodystrophy should be aimed at providing sufficieent doses of whatever vitamin D analog is chosen which cwn both improve bone disease and yet be safe. The hypercalcemia, hypercalcuria and the further decline in renal function that occurs in association with hypervitaminosis D are of major concern (13). No analog of vitamin D is completely safe if the potntial for hypercalcemia is not anticipated and if serum calcium values are not frequently monitored (33) .
As has been shown by studies in uremic adult subjects, bone histology in children reveals osteomalacia, osteitis fibrosa or a combination of the two (34) . The 1a-hydroxy compounds almost always improve or heal pure osteitis in conjunction with a decline in circulating PTH values and in alkaline phosphatase activity. Unfortunately osteomalacia is rarely completely haled (8, 10) .
The value of phosphate restriction has emphasized earlier in this review. However, it is important to realize that reduction of dietary phosphate intake in childrenwithmoderate to severe renal impairment has these major benefits. First, the influence of phosphate on the development of secondary hyperparatyroidism is so pervasive that dietary restriction has been shown to diminish parathyroid gland hypersecretion (15) (16) (17) . Second, the newly recognized importance of phosphate restriction in terms of the regulation of 1,25(OH)2D synthesis in children with moderate renal insufficiency (18) (19) (20) possibly indicates that phosphate restriction may forstall the decline in 1,25(OH)2D synthesis. This point needs to be shown by human studiaes. Third, if less phosphate is ingested then lower doses of aluminum hydroxide are needed, potentially avoiding aluminum toxicity (23) (24) (25) (26) (27) (28) (29) (30) .
Several studies have indicated a dramatic, but unfortunately short-lived, augmentation in height velocity which persist for the first year to year and one half of therapy, but not all studies have found this acceleration in growth (8, 10) . It is important to recall that growth is greatest during the first year of life where a child normally grows by more than 23-25 cm. Obviously, if a child has severe renal osteodystrophy during this period of rapid growth his stature may be impaired. However, few studies have examined the role of early in infants born with obstructive uropathy or another congenital disorder (35) . The defect in mineral homeostasis brought about by uremia and by disruption of the function of the vitamin D -endocrine system, along with other factors such as acidosis and increased water needs, may be important factors contributing to growth failure during infancy. The impact of renal insufficiency on the young child may be devastating with mineral imbalance appearing to play an important role. Finally, older children who develop osteodystrophy because of acquired disease after the age of 2-3 years may not experience growth failure to the same degree, since growth retardation during the first year of life seems to be a dcritical event. These older children, nonetheless, may experience serious bone disease and all of the other usual manifestations of osteodystrophy.
To conclude, the discovery of the vitamin D -endocrine system and the importance of the kidney in its function has clarified our knowledge of the cause of and the manifestations of childhood uremic osteodystrophy. as the vitamin D endocrine system is disturbed in uremia, we can now apreciate the factors contributing to hypocalcemia and to hyperphosphatemia and secondary hypertparathyroidism. Therapy should be directed toward restoring the vitamin D hormone that is not produced by the declining kidney. Further, since phosphate retention may play a role in suppressing 1,25(OH)2D synthesis, particularly in children with moderate renal insufficiency, phosphate intake should also be restricted. However, because of the potential for hypervitaminosis D and aluminum toxicity, these therapeutic measures must be carefully monitored.
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